Drug, across the briefings

Lapatinib across 19 cancers

Lapatinib appears in 19 of the briefings; its FDA label names 1 of those diseases.

Disease	FDA label	Open Targets stage, on which gene	Trials	Active
Breast cancer	label names disease	approved on ERBB2	173	4
Anal cancer		approved on EGFR	—	—
Bladder cancer		approved on ERBB2	8	0
Cervical cancer		approved on ERBB2, EGFR	2	0
Cholangiocarcinoma		approved on ERBB2	4	0
Colorectal cancer		approved on EGFR, ERBB2	8	0
Cutaneous squamous cell carcinoma		approved on EGFR	—	—
Endometrial cancer		approved on ERBB2	2	0
Esophageal cancer		approved on ERBB2, EGFR	6	1
Gallbladder cancer		approved on ERBB2, EGFR	4	0
Gastric cancer		approved on ERBB2	10	1
Glioblastoma		approved on EGFR	7	1
Head and neck cancer		approved on EGFR	12	1
Lung cancer		approved on EGFR, ERBB2	7	0
Nasopharyngeal carcinoma		approved on EGFR	—	—
Osteosarcoma		approved on ERBB2	—	—
Pancreatic cancer		approved on EGFR	3	0
Small intestine cancer		approved on ERBB2	—	—
Vulvar cancer		approved on EGFR	—	—

The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.